Gli autori riferiscono la loro esperienza nella diagnostica delle affezioni del canale spinale mediante introduzione endorachidea di contrasto idrosolubile a bassa concentrazione: 1500 casi.
I progressi tecnologici (TC e RMN) tendono a sostituire in molti casi gli esami con mdc; è augurabile che ciò possa avvenire, in un prossimo futuro, per tutte le patologie. Allo stato attuale occorre ricordare che la mielografia, con la tecnica descritta, non presenta gravi complicazioni e consente in tutti i casi una corretta diagnosi.
AichnerFBauerG: Jopamidol, ein nichtionisches Röntgenkontrastmittel-Veträglichketi aus der Sicht des Neurologen. Wien Klin Woch95: 56–58, 1983.
2.
BacarinLde NicolaT: Iopamiro (B 15000), a nonionic-watersoluble contrst medium for neuroradiology. Part I: Results of a clinical trial for myelography. Neuroradiology23: 81–84, 1982.
3.
BacariniLde NicolaT: Iopamidol (B 15000), a nonionic watersolubre contrast medium for neuroradiology. Part II: Results of a double-blind study of the lumbar epidural plexuses. Neuroradiology23: 147–152, 1982.
4.
BannonKRBraunIF: Comparison of radiographic quality, and adverse reactions in myelography with iopamidol and metrizamide. AJNR4: 312–313, 1983.
5.
BassiPCecchiniA: Myelography with iopamidol, a non ionic water-soluble contrast medium: Incidence of complications. Neuroradiology24: 85–90, 1982.
6.
BelanABendaK: Advantages of a new non ionic contrast medium. The resultss of animal experiment. Ann Radiol21: 279–282, 1978.
7.
BelloniGBonaldiG: Cervical myelography with iopamidol. Neuroradiology21: 97–99, 1981.
8.
BockenheimerSAMHillesheimerW: Clinical experience with iopamidol for myelography. AJNR4: 314–316, 1983.
9.
BonafèAPrereJ: Myélographie cervicale à l'iopamidol. Ann Radiol26: 783–788, 1983.
10.
BonatiFFelderETironeP: Iopamidol new preclinical and clinical data. Invest Radiol15 (Suppl. 6): 310–316, 1980.
11.
BongraniSBaldiG: Influence of contrast media osmolality on isolated rabbit heart performance. Acta Radiol (Diagn.)20: 769–778, 1979.
12.
BongraniSDi DonatoM: Differenti effetti di due mezzi di contrasto sul coefficiente miocardico di estrazione di lattato dopo ventricolografia sinistra. Boll Soc Ital Cardio24: 449–452, 1979.
13.
BoriesJChirasJDrouineauJ: Premiers essais d'un nouveau produit de contraste, l'iopamidol dans l'exploration du canal rachidien. Ann Radiol26: 789–792, 1983.
14.
BorsonFGourdolO: Produits de contraste iodés. I. Action effectrice sur les enzimes sériques. J Radiol64: 55–60, 1983.
15.
BrennanRERapportS: CT-determined canine kidney and urine iodine concentrations following intravenous administration of sodium diatrizoate, metrizamide, iopamidol and-sodium ioxaglate. Invest Radiol17: 95–100, 1982.
16.
BroadbridgeATBaylissSG: Visual evoked response changes following intrathecal injection of water-soluble contrst media: A possible method of assessing nurotoxicity and a comparison of metrazamide and iopamidol. Clin Radiol35: 371–373, 1984.
17.
CahnJBorzeixMGCahnR: Etude expérimentale comparée de la tolérance du système nerveux central à l'administration d'iopamidol, de métrizamide, d'ioxitalamate, d'ioxaglate et d'iocarmate. Ann Radiol26: 774–778, 1983.
18.
CailléJMBidabeAMGuibert-TranierF: Injection intraveineuse d'iopamidol: Utilisation tomodensitométrique dans l'exploration de l'encéphale. Ann Radiol26: 801–806, 1983.
19.
CailléJMGiouxM: Neurotoxicity of nonionic iodinated watersoluble contrast media in myelography: Experimental study. AJNR4: 1185–1189, 1983.
20.
CaputoNChiurullaC: Complicanze da radicolografia e mielografia con iopamidolo: Bilancio su 610 esami. Riv Pat Nery Ment102: 56–68, 1981.
21.
CarellaAFedericoF: Adverse side-effects of metrizamide and iopamidol in myelography. Neuroradiology22: 247–249, 1982.
22.
DawsonPBeckerAHoltonJM: The effect of contrast media on the growth of bacteria. Br J Radiol56: 809–815, 1984.
23.
DawsonPHarrisonMJGWeisblattE: Effect of contrast media on red celle filtrability and morphology. Br J Radiol56: 707–710, 1983.
24.
DawsonPPitfieldJBrittonJ: Contrast media and bronchospasm: A study with iopamidol. Clin Radiol24: 227–239, 1983.
25.
DeanPBKivisariLKormanoM: Contrast enhancement pharmacokinetics of six ionic and nonionic contrast media. Invest Radiol18: 368–374, 1983.
26.
DoyonDLasjauniasPBombartM: Essai de l'iopamidol en artériographie carotidienne interne, externe et vertebrale. Ann Radiol26: 735–736, 1983.
27.
DrayerBPSuslavichF: Clinical trial of iopamidol for lumbosacral myelography. AJNR3: 59–64, 1982.
28.
DrayerBPVassalloC: A double-blind clinical trial of iopamidol versus metrizamide for lumbosacral myelography. J Neurosurg58: 531–537,1983.
29.
DrayerBPWarnerMA: Iopamidol vs metrizamide: A double blind study for cervical myelography. Neuroradiology24: 77–84, 1982.
30.
EldevikOPHaughtonVMSasseEA: Elimination of aqueous myelographic contrast media from the subarachnoid space. Invest Radiol15 (Suppl 6): 260–263, 1980.
31.
FelderEPitrèDGrandiM: Radiopaque contrast media. XLVII - Determination of the optical purity of iopamidol. Farmaco [Prat]37: 3–8, 1982.
32.
FelderEPirèDTironeP: Radiopaque contrast media. XLIV - Preclinical studies with a new nonionic contrast agent. Farmaco [Sci]32: 8355–844, 1977.
FredyD: Iopamidol: étude complémentaire chez quarantedeux patients souffrant d'une pathologie indiquant une myélo-saccoradiculographie. Ann Radiol26: 793–796, 1983.
35.
GalleGHukWArnooldK: Psychopathometric demonstration and quantification of mental disturbances following myelography with metrizamide and iopamidol. Neuroradiology26: 229–233, 1984.
36.
GolmanKOlivecronaH: Exicitation and depression of non-anesthetized rabbits following injection of contrast media into the subarachnoid space. Acta Radiol Suppl362: 83–86, 1980.
37.
GonsetteREBrucherJM: Neurotoxicity of novel water-soluble contrast media for intrathecal application. Invest Radiol15 (Suppl 6): 254–259, 1980.
38.
GuyonJCBonnevilleJF: Etude radioclinique d'une nouveau produit de contraste en radiculographie et myélographie. A propos de cent exmens à l'iopamidol. Ann Radiol26: 797–800, 1983.
39.
HammekeTAHaughtonVM: A preliminary study of cognitive and affective alterations following intrathecal administration of iopamidol or metrizamide. Invest Radiol19 (Suppl 5): 268–271, 1984.
40.
HammerB: Neuroradiologische Erfahrungen mit Iopamidol, einem neuen nichtionischen wasserlöslichen Kontrastmittel. Vergleich mit Metrizamide unter besonderer Berücksichtigung der Nebenerscheinungen and der Pharmakodynamik im Hinblik auf die klinische Anwendung. Radiologe21: 274–281, 1981.
41.
HammerBLacknerW: Iopamidol, a new non-ionic hydrosuluble contrast medium for neurodiology. Neuroradiology19: 119–121, 1980.
42.
HaughtonVMHoKC: Arachnoiditis from myelography with iopamidol, metrizamide and iocarmate compared in the animal model. Invest Radiol15 (Suppl 6): 267–269, 1980.
43.
HammerBLacknerW: Iopamidol, a new non-ionic hydrosoluble contrast medium for neuroradiology. Neuroradiology19: 119–121, 1980.
44.
HaughtonVMHoKC: Arachnoiditis from myelography with iopamidol, metrizamide and iocarmate compared in the animal model. Invest Radiol15 (Suppl 6) 267–269, 1980.
45.
HaughtonVMRimmAA: A blinded clinical comparison of MR imaging and CT in neuroradiology. Radiology106 (3): 751–755, 1986.
KleefielddChirico-PostJ: Iopamidol in lumbar myelography. Surg Neurol20: 165–170, 1983.
48.
LaerumF: Acute damage to human endothelial cells by brief exposure to contrast media in vitro. Radiology147: 681–684, 1983.
49.
LambJTHollandKM: Myelography with iopamidol. AJNR4: 851–853, 1983.
50.
MacphersonPTeasdaleE: Comparison of iopamidol with metrizamide in sub-occipital ventriculography / cisternography. Br J Radiol55: 540–541, 1983.
51.
McAllisterVLHallK: A randomized blind trial of iopamido (Niopam) and metrizamide (Amipaque) in lumbar radiculography. Neuroradiology24: 217–218, 1983.
52.
MasarykTJRossJS: High resolution MR imaging of sequestered lumbar intervertebral disks. AJNR9 (2): 351–358, 1988.
53.
ModicMTMasarykT: Lumbar terminated disk disease and canal stenosis: Prospective evaluation by surface coil MR, CT, and mielography. AJNR7: 709–717, 1986.
54.
ModicMTSteinbergPM: Degenerative disk disease: Assessment of changes in vertebral body marrow with MR imaging. Radiology166: 193–199, 1988.
55.
MoschiniLManaraO: Iopamidol and metrizamide in cervical myelography: Side effects, EEG, and CSF changes. AJNR4: 848–850, 1983.
56.
MuratoreOSaittaS: Elimination kinetic of iopamidol, a new water-soluble nonionic-radiographic contrast medium, analyzed by radioactivation. Experientia39: 119–121, 1983.
57.
PeetersFvan DongenK: Iopamidol for myelography. A clinical trial with a new non-ionic contrast medium. Diagn Imaging52: 313–315, 1983.
58.
PicardLMoretCh: Intérêt de l'iopamidol en tomodensitométrie encéphalique. Etude expérimentale. Ann Radiol26: 807–808, 1983.
59.
PitréDFelderE: Developement, chemistry and physical properties of iopamidol and its analogues. Invest Radiol15 (Suppl 6): 301–309, 1980.
60.
QuiliciNBelloniG: Cisternografia opaca con iopamidolo. Radiol Med67: 965–970, 1981.
61.
RamellaGGrossiG: Contributo neuroradiologico all'uso diagnostico di un mezzo di contrasto idrosolubile non-ionico (Iopamidolo-B 15000). Diagnostica per Immagini3: 178–191, 1983.
62.
RieuwDVialleMC-PoitreauCaron: Utilisation d'un nouveau produit de contraste iodé: L'iopamidol, dans la réalisation d'injections rapides en tomodensitométrie corps entier (dynamic-scan); Ann Radiol26: 809–811, 1983.
63.
RubinJBEnzmannDR: Optimizing conventional MR imaging of the spine. Radiology163: 777–783, 1987.
SignoriniECiorbaE: First experiences with the clinical use of a new hydrosoluble nonionic contrast mediumiopamidol — in the study of the sub-arachnoid space. Rays4: 47–68, 1979.
66.
SilipoPTanfaniGPocekM: Study of the spinal cord with a new water-soluble contrast-media. XXVIII Congress of the Italian Soc of Neurosurger: Roma, 1979.
67.
SmaltinoFCiccarelliR: Mielografia con B 15000, un nuovo mezzo di contrasto idrosolubile non ionico. Aspetti tecnici e prime esperienze cliniche. Radiol Med66: 203–210, 1980.
68.
SovakMDeeutschJARanganathanR: Evaluation of intrathecal contrast media by aversion conditioning in rats. Ivest Radiol17: 101–106, 1982.
69.
SovakMRanganathanRJohnsonM: Spectral analysis of lapine EEG: Neurotoxicologic evaluation of new nonionic contrast media. Invest Radiol15: 452–456, 1980.
70.
SovakMSiefertHMRanganathanR: Combined methods for assessment of neurotoxicity: Testing of new nonionic radiographic media. Invest Radiol15 (Suppl 6): 248–253, 1980.
71.
SpencerCPChrismanCL: Neurotoxicologic effects of the nonionic contrast agent iopamidol on the leptomeningen of the dog. Am J Vet Res43: 1958–1962, 1982.
72.
StoddartPGPWattI: The symptomatic complications of iopamidol (Niopam) and metrizamide (Amipaque) following lumbar radiculography. Br J Radiol57: 349–350, 1984.
73.
ThunF: Erste Erfahrungen mit Solutrast, einem neuen Kontrastmittel zue Myelographie. Roentgenblaetter36: 69, 1983.
74.
TironePBoldriniE: Systemic and local tolerability of iopamidol. An experimental study. Rays6 (Suppl 2) 11–17, 1981.
75.
TironePBoldriniE: Effects of iopamidol on nervous system. An experimental study, Rays7 (Suppl 3): 61–71, 1982.
76.
TironePFerrariD: Pharmacokinetics of iopamidol. Rays7 (Suppl 3): 73–82, 1982.
77.
TironePFerrariDVivianiG: Pharmacokinetics of iopamidol. A clinical study, Rays7 (Suppl 3): 83–86, 1982.
78.
TrevisanCMalagutiC: Iopamidol vs metrizamide myelography: Clinical comparison of side effects. AJNR4: 306–308, 1983.
79.
TurskiPASackettJF: Clinical comparison of metrizamide and iopamidol for myelography. AJNR4: 309–311, 1983.
80.
ValkJ: Gd-DTPA in MR of spinal lesions. AJNR9 (2): 345–351, 1988.
81.
VezinaJLFoxAJ: Double-blind study of the toxicity of intrathecal iopamidol and metrizamide in lumbar myelography. J Can Assoc Radiol35: 257–258, 1984.
